Tiziana Life Sciences (TLSA) Payables (2017 - 2025)

Tiziana Life Sciences has reported Payables for 9 years, with the latest figure at $10.5 million in Q4 2025.

• On a quarterly basis, Payables rose 44.67% year-over-year to $10.5 million in Q4 2025; TTM through Dec 2025 was $10.5 million, a 44.67% increase from a year earlier, with the FY2025 full-year figure at $10.5 million, up 44.67% from the prior year.
• Payables was $10.5 million for Q4 2025 at Tiziana Life Sciences, up from $7.2 million in the prior quarter.
• The five-year high for Payables was $10.5 million in Q4 2025, with the low at $3.8 million in Q2 2023.
• Average Payables over 5 years is $7.2 million, with a median of $7.2 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Payables plunged 37.48% in 2022, then soared 137.04% in 2024.
• Over 5 years, Payables stood at $7.5 million in 2021, then decreased by 13.32% to $6.5 million in 2022, then retreated by 2.22% to $6.4 million in 2023, then grew by 13.2% to $7.2 million in 2024, then jumped by 44.67% to $10.5 million in 2025.
• The last three Payables figures came in at $10.5 million (Q4 2025), $7.2 million (Q2 2025), and $7.2 million (Q4 2024), per Business Quant data.